We are reinventing the fundamental science underlying the development of new medicines and their use in individual patients.
The Laboratory of Systems Pharmacology (LSP) uses a team science approach to advance the fundamental science and technology needed to develop new medicines and personalized patient care.
We study the molecular causes of disease, how drugs exert their therapeutic and adverse effects, how clinical trials are designed and interpreted, and how machine learning and AI can help identify new molecular targets in diseases like cancer, Alzheimer’s, tuberculosis, and chronic pain.
The LSP is a research and education program that is part of the Harvard Program in Therapeutic Science (HiTS). Our organization prepares students and fellows for leadership roles in academic research, industry, and government service.
Explore LSP Research
Twitter @Harvard_Lab
Hugues de The and I want to remind you that nothing has cured more cancer patients than conventional chemotherapy!!! Think you understand how it selectively kills cancer cells so well? Take a look inside. @DanaFarber @DanaFarberNews
Important and fascinating article by @DrTonyLetai and Hugues de Thé
How does chemotherapy have a large enough therapeutic window to cure certain cancers?
🚨 Exciting News! 🚨
The largest analysis of cell and gene therapy clinical development success probabilities is here!
What we did:
- Analyzed 900+ cell and gene therapies and 2,500 clinical trials to build 1,900 development programs.
Read here
Starting shortly - it looks like a great line up of talks!
✨LSP postdoc Emmanuel Ogbonna will speak at noon!